Fig. 1
From: Epstein–Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer
a IgG recognition of CMV-pp65 in plasma of healthy donors and patients with brain tumor or pancreatic cancer. Box stars indicate statistical significance of IgG levels in response to CMV-pp65 with all the other groups. Medians are shown for each group when superior to 0. Kruskal–Wallis test followed by Dunn’s post-test was performed to gauge statistical significance *p < 0.05; **p < 0.01; ***p < 0.001. b Survival of the patients with GBM based on the CMV-specific IgG levels. Median concentration of CMV-specific IgG levels was used as a cut-off to generate two groups: individual with “high” vs. “low” CMV-specific IgG. Top panel: all GBM patients (n = 151). Bottom panel: GBM patients with detectable anti-CMV IgG (n = 107). GBM glioblastoma multiforme, A astrocytoma, OA/OD oligoastrocytoma/oligodendroglioma, M metastatic disease, Panc Cancer pancreatic cancer, HD healthy donor and Post-OP post-operation